The DOI matches its Crossref record; 84 of the 94 references it cites were found in a registry or an index, and 10 are not checked yet; 28 of the 138 sources its claims cite were checked for support.
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Open accessPublished version of a preprint
Abstract
KRAS is the most frequently mutated oncogene, harboring mutations in approximately one in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment paradigm for patients with KRASG12C-mutated non–small cell lung cancer and colorectal cancer. The success of addressing a previously elusive KRAS allele has fueled drug discovery efforts for all KRAS mutants. Pan-KRAS drugs have the potential to address broad patient populations, including KRASG12D-, KRASG12V-, KRASG13D-, KRASG12R-, and KRASG12A-mutant or KRAS wild-type–amplified cancers, as well as cancers with acquired resistance to KRASG12C inhibitors. Here, we review actively pursued allele-specific and pan-KRAS inhibition strategies and their potential utility. Significance: Mutant-selective KRASG12C inhibitors target a fraction (approximately 13.6%) of all KRAS-driven cancers. A broad arsenal of KRAS drugs is needed to comprehensively conquer KRAS-driven cancers. Conceptually, we foresee two future classes of KRAS medicines: mutant-selective KRAS drugs targeting individual variant alleles and pan-KRAS therapeutics targeting a broad range of KRAS alterations.
Verified 2026-10-06 · 10 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 4 Not valid · 66 Not checked · 37 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“While KRASG12C inhibitors deliver clinical benefit, all patients who achieved an objective response ultimately progressed on treatment with sotorasib in a Phase II study (24).”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > FURTHER OPPORTUNITIES FOR PAN-KRAS DRUGS > ACQUIRED RESISTANCE TO MUTANT-SELECTIVE KRASG12C INHIBITORS
What the sources say
- Disputedcites [24] Skoulidis, 2021, Sotorasib for lung cancers with KRAS p.G12C mutation, N Engl J Med sourceExperimental — accuracy not yet measured
The Results (Efficacy) report 46 objective responses, but state that at the data cutoff, 16 of those patients were still receiving sotorasib without disease progression. The study therefore does not report that all responders progressed on treatment; it cannot establish what happened to those 16 patients later. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“KRAS is the most frequently mutated oncogene”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > Abstract
What the sources say
- Partly supportedcites [3] Prior, 2020, The frequency of Ras mutations in cancer, Cancer Res sourceExperimental — accuracy not yet measured
The Introduction (page not provided) reports that KRAS accounts for 75% of Ras-mutant cancers and is the most frequently mutated of the three Ras isoforms in 19 of 29 cancer types. This supports describing KRAS as frequently mutated, but the paper does not establish the citing sentence’s stronger claim that it is the most frequently mutated oncogene overall. (LLM, conf=0.86)
- Could not verifycites [4] Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov sourceExperimental — accuracy not yet measured
The passages on mutation visualization and alteration frequency (section labeled Abstract; page unavailable) discuss BRCA1, RB-pathway genes, and other examples, but do not address KRAS. Searches for “KRAS most frequently mutated oncogene” and “KRAS” found no passage establishing its mutation-frequency ranking. (LLM, conf=0.75)
- Partly supportedcites [5] AACR Project GENIE Consortium, 2017, AACR Project GENIE: powering precision medicine through an international consortium, Cancer Discov sourceExperimental — accuracy not yet measured
The Comparison with TCGA section reports KRAS mutations in 27% of non–small cell lung cancers and 47% of colorectal cancers in GENIE, supporting that KRAS is frequently mutated in those cancers. It does not establish that KRAS is the most frequently mutated oncogene across human cancers, as the citing sentence states. No page number is available in our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In heterozygous KRAS mutant tumor cells, RAS signaling can be supplemented and cross-regulated by RTK-WT RAS signaling.”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > INTRODUCTION > INDIRECT THERAPEUTIC PAN-KRAS CONCEPTS
What the sources say
- Partly supportedcites [12] Hofmann, 2021, BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition, Cancer Discov sourceExperimental — accuracy not yet measured
The Introduction describes SOS1-mediated activation of RAS and feedback regulation, and the Results report signaling measurements in heterozygous KRAS-mutant tumor cells. The paper does not explicitly show that RTK-driven wild-type RAS signaling supplements and cross-regulates signaling in those heterozygous cells; that specific connection is not established by the cited passages. Page numbers are unavailable in our copy. (LLM, conf=0.82)
- Partly supportedcites [43] Liu, 2021, Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling, Clin Cancer Res sourceExperimental — accuracy not yet measured
The section on TNO155 and KRAS G12C inhibitors describes feedback signaling through wild-type KRAS, HRAS, and NRAS and reports combination effects in heterozygous KRAS G12C cell lines (page not available in our copy). This supports the proposed interaction between mutant-KRAS and wild-type-RAS signaling, but the paper’s evidence is specific to KRAS G12C models and inhibitor-induced feedback, not heterozygous KRAS-mutant tumor cells generally. (LLM, conf=0.85)
- Not checked yetcites [45] Hofmann, 2021, Trial in process: phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan, Cancer Res source
- Partly supportedcites [46] Hayes, 2013, Mutant and wild-type Ras: co-conspirators in cancer, Cancer Discov sourceExperimental — accuracy not yet measured
The Findings section describes RTK signaling activating WT Ras and potentially bypassing blocked mutant-Ras signaling; it also describes antagonism between mutant Ras and EGFR signaling. But the studied KRAS-mutant cell line was homozygous, not heterozygous, for mutant KRAS, so the source does not establish the claim for heterozygous KRAS-mutant tumor cells. No page number is provided in our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Initial data suggest that a higher tumor mutational burden occurs in the overall KRAS mutant population, potentially resulting in improved response to immune checkpoint inhibition (71).”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > INTRODUCTION > PATIENT POPULATIONS ADDRESSABLE BY PAN-KRAS DRUGS
What the sources say
- Partly supportedcites [71] Sun, 2021, Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer, JAMA Oncol sourceExperimental — accuracy not yet measured
The introduction (page not provided) associates KRAS variants in NSCLC with responsiveness to ICI monotherapy, and the Results report better survival with ICI monotherapy for patients with KRAS variants than for those with KRAS wild type. But the paper does not report tumor mutational burden or link it to the observed outcomes; its analysis is also restricted to advanced, PD-L1-high nonsquamous NSCLC, not the overall KRAS-mutant population. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“Non-G12C KRAS mutant NSCLC tumors are distinct from KRASG12C-mutated lung cancers in terms of co-mutation of tumor suppressor genes.”
§ Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants > INTRODUCTION > PATIENT POPULATIONS ADDRESSABLE BY PAN-KRAS DRUGS
What the sources say
- Could not verifycites [5] AACR Project GENIE Consortium, 2017, AACR Project GENIE: powering precision medicine through an international consortium, Cancer Discov sourceExperimental — accuracy not yet measured
The Comparison with TCGA section reports KRAS p.G12 enrichment and KRAS–EGFR mutual exclusivity in non–small cell lung cancer. It does not compare G12C with non-G12C tumors or report differences in tumor-suppressor co-mutations; searches for those terms and for TP53, STK11, and KEAP1 found no matching passage in our copy. (LLM, conf=0.76)
- Not checked yetcites [67] Aggarwal, 2020, Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB), Ann Oncol source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
53 more claims · 2 with their cited sources checked
Create a free account to see all 121 claims and to verify the 110 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 53
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Third, 12–14% of KRAS mutations in NSCLC are KRASG12C, presenting a promising patient group that would directly benefit from KRAS(G12C) inhibition89.”
From Advances in covalent drug discovery (2022) · cites this paper as [89]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Collectively, these findings indicate that resistance to KRAS-targeted therapy is driven by a complex interplay between KRAS-specific genomic evolution, general signaling adaptation, phenotypic plasticity, and tumor microenvironmental dynamics [12].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS mutations are most commonly found in non-small cell lung cancer (NSCLC; 30~35%), pancreatic ductal adenocarcinoma (PDAC; ~90%) and colorectal cancer (CRC; 45~50%) [10–12], and are associated with a worse prognosis [13–15].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Preclinical and clinical studies, however, have demonstrated that cancers lose sensitivity to KRASG12Ci and re-establish RAS-MAPK signaling through multiple mechanisms, including increased activation of mutant or wild-type (WT) RAS and/or gain of upstream/downstream bypass events1,7,9,10,13,14.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Unlike KRAS G12C, KRAS G12D lacks a targetable cysteine residue for covalent inhibition [12,14,15].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [12]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“Preclinical studies suggest that sotorasib and adagrasib can induce a more proinflammatory and TIL-infiltrated TME in mouse models, translating into durable complete responses in combination with anti–PD-1 therapy (21, 74).”
BackgroundAACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Self-citation
Research works printed but not linked: 2
- Kraut, 2021, Expanding the reach of precision oncology by drugging all KRAS mutants
- Scala, 2008, Generation and characterization of triple knockout mice for H, N and K-ras genes [dissertation
Cited by
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Pan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth
Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06123-3 · Cited by 534
Self-citationNeoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Metadata
- Authors
- Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N.
- Affiliations
- Boehringer Ingelheim (Austria) (AT)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Kraut, Norbert
- Venue
- Cancer Discovery
- Published
- 2022-01-19
- Volume
- 12
- Issue
- 4
- Pages
- 924-937
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC9394389
- OpenAlex
- W4205933836
- Semantic Scholar
- 62e5c29c0dfc65c8d643cf80f4f3e78cdda96ed5
- Cited by
- 336
- References
- 94
- Citations by year
- 2026: 59 · 2025: 86 · 2024: 80 · 2023: 78 · 2022: 33
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS mutation, pan-KRAS inhibitors, KRAS G12D, precision oncology, KRAS-driven cancers, non-small cell lung cancer, colorectal cancer
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Oncogenes, Proto-Oncogene Proteins p21(ras), Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-1331
- The paper
- Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022). Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-1331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.